Tag: Bayer

Bayer AG is a German multinational chemical, pharmaceutical and life sciences company. It is headquartered in Leverkusen, where its illuminated sign is a landmark. Bayer’s primary areas of business include human and veterinary pharmaceuticals; consumer healthcare products; agricultural chemicals and biotechnology products; and high value polymers.

Bayer to Obtain Full Rights on Two Loxo’s Drugs

Bayer exercised option under change-in-control clause in it’s agreement with Loxo Oncology to obtain full licensing rights for the two TRK inhibitor agents. Bayer has exercised its option, under a ...

Moberg Pharma and Bayer Entered into Agreement

Moberg Pharma AB has signed an exclusive license agreement with Bayer for commercialization of MOB-015 in Europe. Under the agreement, Moberg Pharma is eligible to receive up to EUR 50 million conting...

Liver Cancer Drug of Bayer has Final NICE Recommendation

Bayer’s Stivarga has received a final green light from the National Institute for Health and Care Excellence (NICE) for use by the NHS to treat advanced liver cancer. Stivarga (regorafenib) is reco...

Big Pharma Companies to Raise Drug Prices in January

Novartis AG and Bayer AG are among nearly 30 drugmakers that have taken steps to raise the U.S. prices of their medicines in January, ending a self-declared halt to increases made by a pharma industry...

Bayer Updates Prescription for RRMS Drug

Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved the inclusion of new safety data on pregnancy in the prescribing information for Betaseron® (Interferon beta 1b, IFN...

Bayer plans to reinforce its life sciences businesses

The Bayer Group aims to strengthen its core life science businesses through a series of portfolio, efficiency and structural measures designed to enhance productivity and innovation.

Bayer obtains EU approval for hemophilia drug

Bayer announced that Jivi® has been approved by the European Commission for the treatment and prophylaxis of bleeding in previously treated patients 12 years of age or older with hemophilia A.

Cyclica to collaborate with Bayer on drug discovery programs

drug development
Cyclica, a Canadian biotechnology company, announced a collaboration with Bayer to advance drug discovery programs by gaining insights into the polypharmacological profiles of small molecules.

Bayer rewards Skolkovo’s innovation biomedicine projects

Three innovative biomed projects were selected as the winners of the Patents Power competition last week organised by the Skolkovo Foundation, the pharmaceutical giant Bayer and Rospatent.

Bayer updates its pharmacovigilance systems with Genpact’s AI suite

Genpact signed a multi-year agreement with Bayer under which Genpact’s Pharmacovigilance Artificial Intelligence (PVAI) suite of capabilities.

Bayer and Orion prostate cancer drug completed phase III trial

Orion and Bayer have completed the phase III trial of darolutamide, the novel oral androgen receptor antagonist for the treatment of patients with non-metastatic castration-resistant prostate cancer.

Israeli drug discovery company receives $7.8 million funding from Bayer

Compugen, an Israeli clinical-stage cancer immunotherapy and predictive target discovery company, has earned a $7.8 million milestone payment from German pharma giant Bayer.

Bayer and Skolkovo set up a competition for biotech startups

The Skolkovo has teamed up with Bayer to launch a competition to help biotech startups advance their projects and secure their intellectual property rights.

Evotec partner Haplogen starts drug discovery collaboration with Bayer

Haplogen, a biotechnology company, has entered into a multi-year drug discovery and development collaboration with Bayer AG to identify new therapeutics with applications in pulmonary diseases.

Janssen and Bayer will close their South Korean facilities

Janssen and Bayer will join global pharmaceutical companies that have pulled their manufacturing facilities out of Korea over rising payroll costs and intensifying conflicts with unions.

LEO Pharma will gain Bayer’s prescription dermatology portfolio

The portfolio to be acquired includes branded topical prescription treatments for acne, fungal skin infections and rosacea, and a range of topical steroids.